As we see the digital re-invention of industries, our executives, directors, and advisors are resolute in delivering AI-driven solutions to transform how organizations access, identify, and monitor innovation to anticipate the future and eliminate uncertainties.Together they have created a platform that is shaping business strategy and driving corporate decisions for the clients we are privileged to serve.

Our dedicated team of domain experts is making a global impact by building business solutions utilizing artificial intelligence and machine learning technologies to expedite innovation across industries.

Krishnan Nandabalan, Ph.D.

President and CEO, Inveniai and CO-Founder Bioxcel Corporation

Over the past ten years, Dr. Nandabalan has pioneered the development of big data analytics, AI, and ML and its application in monitoring emerging innovation through the assimilation and query of large data sets. This resulted in the successful spinout of the biotech company BioXcel Therapeutics (NASDAQ: BTAI) as well as the technology spinout InveniAI Corporation, where he is now the President and CEO. Dr. Nandabalan has over two decades of experience in the pharmaceutical and biotechnology industries, including operations, and BD. He has extensive experience in business development including M&A and in/out-licensing and has completed deals with key industry players such as Pfizer, J&J, AstraZeneca, Pharmacia, BMS, Biogen, Millennium Pharmaceuticals, Merck KGaA, Organon, Daiichi Sankyo, Otsuka, Takeda, and Kyowa Hakko Kirin among others. He served as VP, Corporate Development at Genaissance Pharmaceuticals, a trailblazer in the widespread acceptance of pharmacogenomics. Before this, he was Group Leader of the Functional Genomics Group at CuraGen Corp. He has 12 issued patents and published in leading journals such as Cell and Science. He holds a Ph.D. in Biochemistry and Molecular Biology from the Indian Institute of Science, India, and was a Post-Doctoral Fellow at Yale University. Dr. Nandabalan has a thorough understanding of the applications of artificial intelligence to drive innovation.

Aman Kant

Chief Business Officer

Mr. Kant is a seasoned business development executive with over a decade of experience in establishing and executing long-term strategic goals, commercial excellence, and operational efficiency. He has over 15 years of experience in strategy, deal-making, alliance management, and extensive knowledge in building and leading business development teams to consummate more than two-dozen significant transactions. He is highly focused and adept at delivering value to partners through technology solutions with a depth of knowledge across big data and artificial intelligence impacting biopharma innovation. Prior to joining InveniAI, Mr. Kant played a significant role in the parent Company, BioXcel Corporation, where he led the assessment and negotiation of numerous collaborations that expanded and strengthened the value proposition of big data analytics tools across the R&D value chain. Mr. Kant holds a B.Tech in Biotechnology.

James Fitzgerald

Vice President of Sales & Business Development

James is a multi-industry executive, with extensive international P&L experience. He has built global teams, with new solutions and services, expanding markets, generating business value, and delivering results for clients across various global industry sectors. These include commercial & government, manufacturing, aftermarket, aerospace & defense, travel & transportation, rail, vessels, food processing, chemicals, pharmaceuticals, R&D, hospitals, automotive, retail, food & beverage, supply-chain, oil & gas, and banking & finance. James has provided solutions and services around digital transformation, artificial intelligence, machine learning, IoT, and Blockchain to some of the world’s largest organizations. Prior to this, James has worked for IBM, Koverse, Mxi Technologies, Ramco Systems, and Intermec Technologies (now Honeywell Scanning). James has a management degree in business administration from Post University in Waterbury, Connecticut. He is also a speaker and presenter to various aligned industry groups.

Anita Ganjoo, Ph.D.

Director, Communications

Anita is a marketing and corporate communications specialist with close to 10 years of experience. Dr. Ganjoo has created, developed, and managed content for all corporate functions, including marketing, media, and investor relations, as well as developing and implementing communications goals and strategies. She has primarily worked for start-ups that have grown through to IPO. She previously worked for BioXcel Corporation, where she headed their corporate communications, and prior to this, she worked in scientific communications at Genaissance Pharmaceuticals, a trailblazer in pharmacogenomics and personalized medicine. She completed two Post Doctoral Fellowships at Lund University, Sweden, and at The University of Reading, UK, where she also received her Ph.D. in Biotechnology. She is the author of numerous publications on the applications of aqueous two-phase systems in protein purification.

our

MANAGEMENT

Krishnan Nandabalan, Ph.D.

Aman Kant

James Fitzgerald

Anita Ganjoo, Ph.D.

BOARD OF

DIRECTORS

AMIT AGRAWAL

DEMETRIOS KYDONIEUS

JONATHAN ZALEVSKY PH.D.

KRISHNAN NANDABALAN, PH.D.

VIMAL MEHTA PH.D.

AMIT AGRAWAL

Global Head of Portfolio Strategy and Management, Novartis

Amit Agrawal drives pharma industry’s largest clinical development portfolio. He joined Novartis in 2018 from Amgen where he was Head of Corporate Strategy. At Amgen, he was responsible for managing strategic planning processes and communications to the Board, company-wide resource allocation planning and transformation, and driving M&A (e.g., Amgen’s acquisition of Onyx) and capital investment projects. Prior to Amgen, he was at McKinsey and finished a postdoc from MIT, where he developed and tested siRNA delivery formulations in ovarian cancer and Glioblastoma mouse models. He finished his graduate studies in Biomedical Engineering/nanotechnology from Georgia Tech, where he developed reagents, assays, and instruments for ultrasensitive biological detection/ imaging at Georgia Tech. He has an undergraduate and master’s degree in Chemistry from the Indian Institute of Technology, Kanpur. He has also worked at two startups, one of which was a small, public biotech company where he served as chief operating officer. He is an author on over 20 research articles, and in his spare time, he plays percussions for charitable causes.

DEMETRIOS KYDONIEUS

President & CBO, R-Pharm U.S.

Mr. Kydonieus is a senior pharmaceutical executive with proven success leading multibillion-dollar global transactions and complex negotiations. He has been instrumental in assisting small, medium, and large BioPharma companies in executing their corporate strategies resulting in significant growth and shareholder value. In 2014, he teamed up with Mark Pavao to create a differentiated specialty BioPharma company. The opportunity to work with Russia's premier pharmaceutical company, R-Pharm JSC, presented a unique opportunity to accelerate the growth and importance of the BioPharma start-up (R-PHARM US). Prior to this, he served as Vice President, Strategy, Alliances, and Transactions (SAT) at Bristol Myers Squibb (BMS), where he was instrumental in implementing the BioPharma transformation and the String of Pearls strategy. Mr. Kydonieus began working at BMS as Director, Worldwide Regulatory Affairs in the Health Care Group. After leaving the Health Care Group, he joined the Corporate Strategy and Issues Management Group as Director, Business Risk Management, where he identified and helped manage the most significant risks to the BMS strategy. Mr. Kydonieus earned his MBA from Duke University, Fuqua School of Business.

JONATHAN ZALEVSKY PH.D.

SVP, Nektar Therapeutics

Dr. Zalevsky has over 15 years of research and discovery experience in large pharmaceutical and biotech. Dr. Zalevsky joined Nektar in 2015 to lead biological and translational research and guide strategy for the Nektar discovery portfolio. Dr. Zalevsky’s expertise in immunology, as well as his experience across biological modalities and therapeutic areas, have helped fuel the growth of the company’s immuno-oncology and immunology pipeline. He led the discovery and preclinical development for NKTR-358 (a T regulatory cell stimulatory agent developed for auto-immune diseases with partner Eli Lilly & Co.) and NKTR-262 (a small molecule TLR agonist developed in combination with NKTR-214). Before joining Nektar, Dr. Zalevsky was Global Vice President and Head of the Inflammation Drug Discovery Unit at Takeda Pharmaceuticals. At Takeda, he was responsible for an immunology pipeline that spanned from early target discovery to late-stage development. Before this, Dr. Zalevsky held several research and development positions at Xencor, where he was responsible for the discovery and development of Xencor's first four clinical-stage assets. He received his Ph.D. in Biochemistry from the Tetrad Program at the University of California at San Francisco (UCSF).

KRISHNAN NANDABALAN, PH.D.

President & CEO, Inveniai and CO-Founder Bioxcel Corporation

VIMAL MEHTA PH.D.

CEO & Founder, Bioxcel Therapeutics

Dr. Mehta brings over two decades of experience in the pharma and biotech industry, during which he has successfully designed and implemented innovative solutions, established global commercial operations, and led cross-functional teams. During his career, he has garnered a deep understanding of the biopharma and healthcare ecosystem and is actively involved in generating a range of value creation initiatives in corporate strategy and planning, global business development, and corporate fundraising. He is a Co-founder, Chairman of the Board and Chief Executive Officer of BioXcel Corporation. Dr. Mehta has held various senior scientific and business development positions, including Senior Vice President of Business Development at Inpharmatica Ltd. and Jubilant Life Sciences. Previously, Dr. Mehta served as Business Development Manager at CuraGen Corporation. Dr. Mehta holds a Ph.D. in chemistry from the University of Delhi, India, and completed a Post-Doctoral Fellowship in Chemistry at the University of Montpellier, France.

OUR TEAM

InveniAI – Innovate with Intelligence

Krishnan Nandabalan, Ph.D.

President and CEO, Inveniai and CO-Founder Bioxcel Corporation

Aman Kant

Chief Business Officer

James Fitzgerald

Vice President of Sales & Business Development

Anita Ganjoo, Ph.D.

Director, Communications

our

MANAGEMENT

BOARD OF

DIRECTORS

AMIT AGRAWAL

Global Head of Portfolio Strategy and Management, Novartis

DEMETRIOS KYDONIEUS

President & CBO, R-Pharm U.S.

JONATHAN ZALEVSKY PH.D.

SVP, Nektar Therapeutics

KRISHNAN NANDABALAN, PH.D.

President & CEO, Inveniai and CO-Founder Bioxcel Corporation

VIMAL MEHTA PH.D.

CEO & Founder, Bioxcel Therapeutics